FR3035326B1 - Utilisation de la (4-hydroxy-2-methyl-1,1-dioxido-2h-benzo[e][1,2]thiazin-3-yl)(naphtalen-2-yl)methanone dans la prevention et/ou le traitement de la steatohepatite non-alcoolique - Google Patents

Utilisation de la (4-hydroxy-2-methyl-1,1-dioxido-2h-benzo[e][1,2]thiazin-3-yl)(naphtalen-2-yl)methanone dans la prevention et/ou le traitement de la steatohepatite non-alcoolique

Info

Publication number
FR3035326B1
FR3035326B1 FR1553574A FR1553574A FR3035326B1 FR 3035326 B1 FR3035326 B1 FR 3035326B1 FR 1553574 A FR1553574 A FR 1553574A FR 1553574 A FR1553574 A FR 1553574A FR 3035326 B1 FR3035326 B1 FR 3035326B1
Authority
FR
France
Prior art keywords
dioxido
thiazin
methanone
naphthalen
benzo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR1553574A
Other languages
English (en)
French (fr)
Other versions
FR3035326A1 (fr
Inventor
Marie Lamothe
Didier Junquero
Grand Bruno Le
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pierre Fabre Medicament SA
Original Assignee
Pierre Fabre Medicament SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR1553574A priority Critical patent/FR3035326B1/fr
Application filed by Pierre Fabre Medicament SA filed Critical Pierre Fabre Medicament SA
Priority to US15/568,085 priority patent/US20180140609A1/en
Priority to BR112017021586-1A priority patent/BR112017021586A2/pt
Priority to RU2017137262A priority patent/RU2017137262A/ru
Priority to PCT/EP2016/058760 priority patent/WO2016169983A1/fr
Priority to EP16717911.8A priority patent/EP3285774B1/fr
Priority to CA2981933A priority patent/CA2981933A1/fr
Priority to AU2016251601A priority patent/AU2016251601A1/en
Priority to CN201680023190.6A priority patent/CN107530355A/zh
Priority to KR1020177030299A priority patent/KR20170139030A/ko
Priority to MX2017013453A priority patent/MX2017013453A/es
Priority to JP2017555239A priority patent/JP2018513175A/ja
Publication of FR3035326A1 publication Critical patent/FR3035326A1/fr
Application granted granted Critical
Publication of FR3035326B1 publication Critical patent/FR3035326B1/fr
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
FR1553574A 2015-04-21 2015-04-21 Utilisation de la (4-hydroxy-2-methyl-1,1-dioxido-2h-benzo[e][1,2]thiazin-3-yl)(naphtalen-2-yl)methanone dans la prevention et/ou le traitement de la steatohepatite non-alcoolique Expired - Fee Related FR3035326B1 (fr)

Priority Applications (12)

Application Number Priority Date Filing Date Title
FR1553574A FR3035326B1 (fr) 2015-04-21 2015-04-21 Utilisation de la (4-hydroxy-2-methyl-1,1-dioxido-2h-benzo[e][1,2]thiazin-3-yl)(naphtalen-2-yl)methanone dans la prevention et/ou le traitement de la steatohepatite non-alcoolique
CN201680023190.6A CN107530355A (zh) 2015-04-21 2016-04-20 (4‑羟基‑2‑甲基‑1,1‑二氧‑2H‑苯并[e][1,2]噻嗪‑3‑基)(萘‑2‑基)甲酮在预防和/或治疗非酒精性脂肪性肝炎中的用途
RU2017137262A RU2017137262A (ru) 2015-04-21 2016-04-20 Применение (4-гидрокси-2-метил-1,1-диоксид-2н-бензо[е][1,2]тиазин-3-ил)(нафталин-2-ил)метанона для профилактики и/или лечения неалкогольного стеатогепатита
PCT/EP2016/058760 WO2016169983A1 (fr) 2015-04-21 2016-04-20 Utilisation de la (4-hydroxy-2-methyl-1,1-dioxido-2h-benzo[e][1,2]thiazin-3-yl)(naphthalen-2-yl) methanone dans la prevention et/ou le traitement de la steatohepatite non-alcoolique
EP16717911.8A EP3285774B1 (fr) 2015-04-21 2016-04-20 Utilisation de la (4-hydroxy-2-methyl-1,1-dioxido-2h-benzo[e][1,2]thiazin-3-yl)(naphthalen-2-yl) methanone dans la prevention et/ou le traitement de la steatohepatite non-alcoolique
CA2981933A CA2981933A1 (fr) 2015-04-21 2016-04-20 Utilisation de la (4-hydroxy-2-methyl-1,1-dioxido-2h-benzo[e][1,2]thiazin-3-yl)(naphthalen-2-yl) methanone dans la prevention et/ou le traitement de la steatohepatite non-alcoolique
US15/568,085 US20180140609A1 (en) 2015-04-21 2016-04-20 Use of (4-hydroxy-2-methyl-1,1-dioxido-2h-benzo[e][1,2]thiazine-3-yl)(naphthalene-2-yl) methanone in the prevention and/or treatment of non-alcoholic steatohepatitis
BR112017021586-1A BR112017021586A2 (pt) 2015-04-21 2016-04-20 Uso de (4-hidróxi-2-metil-1,1-dióxido-2h-benzo-[e][1,2] tiazin-3-il)(naftalen-2-il) metanona na prevenção e/ou no tratamento de esteato-hepatite não alcoólica
KR1020177030299A KR20170139030A (ko) 2015-04-21 2016-04-20 비-알코올성 지방간염의 예방 및/또는 치료에서 (4-하이드록시-2-메틸-1,1-디옥시도-2H-벤조[e][1,2]티아진-3-일)(나프탈렌-2-일)메탄온의 용도
MX2017013453A MX2017013453A (es) 2015-04-21 2016-04-20 Uso de (4-hidroxi-2-metil-1,1-dioxido-2h-benzo [e] [1, 2] tiazin-3-il) (naftalen-2-il) metanona en la prevencion y/o tratamiento de esteatohepatitis no alcoholica.
JP2017555239A JP2018513175A (ja) 2015-04-21 2016-04-20 非アルコール性脂肪性肝炎の予防および／または治療における（４−ヒドロキシ−２−メチル−１，１−ジオキシド−２Ｈ−ベンゾ［ｅ］［１，２］チアジン−３−イル）（ナフタレン−２−イル）メタノンの使用
AU2016251601A AU2016251601A1 (en) 2015-04-21 2016-04-20 Use of (4-hydroxy-2-methyl-1,1-dioxido-2H-benzo(e)(1,2)thiazine-3-yl)(naphthalene-2-yl) methanone in the prevention and/or treatment of non-alcoholic steatohepatitis

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1553574A FR3035326B1 (fr) 2015-04-21 2015-04-21 Utilisation de la (4-hydroxy-2-methyl-1,1-dioxido-2h-benzo[e][1,2]thiazin-3-yl)(naphtalen-2-yl)methanone dans la prevention et/ou le traitement de la steatohepatite non-alcoolique

Publications (2)

Publication Number Publication Date
FR3035326A1 FR3035326A1 (fr) 2016-10-28
FR3035326B1 true FR3035326B1 (fr) 2017-05-12

Family

ID=53484018

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1553574A Expired - Fee Related FR3035326B1 (fr) 2015-04-21 2015-04-21 Utilisation de la (4-hydroxy-2-methyl-1,1-dioxido-2h-benzo[e][1,2]thiazin-3-yl)(naphtalen-2-yl)methanone dans la prevention et/ou le traitement de la steatohepatite non-alcoolique

Country Status (12)

Country Link
US (1) US20180140609A1 (OSRAM)
EP (1) EP3285774B1 (OSRAM)
JP (1) JP2018513175A (OSRAM)
KR (1) KR20170139030A (OSRAM)
CN (1) CN107530355A (OSRAM)
AU (1) AU2016251601A1 (OSRAM)
BR (1) BR112017021586A2 (OSRAM)
CA (1) CA2981933A1 (OSRAM)
FR (1) FR3035326B1 (OSRAM)
MX (1) MX2017013453A (OSRAM)
RU (1) RU2017137262A (OSRAM)
WO (1) WO2016169983A1 (OSRAM)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102177304B1 (ko) 2018-07-23 2020-11-10 제이투에이치바이오텍 (주) 비알콜성 지방간염의 예방 또는 치료용 약학 조성물
RU2706026C1 (ru) * 2018-12-28 2019-11-13 Государственное бюджетное учреждение здравоохранения города Москвы Московский клинический научно-практический центр им. А.С. Логинова Департамента здравоохранения города Москвы Способ лечения неалкогольной жировой болезни печени и сахарного диабета второго типа

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0107383D0 (en) * 2001-03-23 2001-05-16 Univ Edinburgh Lipid profile modulation
JP2007197369A (ja) * 2006-01-26 2007-08-09 Sankyo Co Ltd ベンゾチアジン誘導体
FR2942797B1 (fr) * 2009-03-03 2011-04-29 Pf Medicament Derives de benzothiazines, leur preparation et leur application a titre de medicaments
KR101134447B1 (ko) * 2009-11-30 2012-04-10 에스케이 주식회사 아세트아마이드기를 갖는 사이클릭설폰아미드 유도체, 이의 제조방법 및 이를 함유하는 약학 조성물
JP2011213685A (ja) * 2010-04-01 2011-10-27 Kowa Co ベンゾイミダゾリルピペリジン誘導体を有効成分とする１１β−ヒドロキシステロイドデヒドロゲナーゼ１阻害剤
EP2563780B1 (en) * 2010-04-29 2015-05-06 The University Of Edinburgh 3,3-disubstituted-(8-aza-bicyclo[3.2.1]oct-8-yl)-[5-(1h-pyrazol-4-yl)-thiophen-3-yl]-methanones as inhibitors of 11(beta)-hsd1
JP5901025B2 (ja) * 2011-04-19 2016-04-06 第一三共株式会社 テトラヒドロチアゼピン誘導体

Also Published As

Publication number Publication date
WO2016169983A1 (fr) 2016-10-27
RU2017137262A3 (OSRAM) 2019-09-30
CN107530355A (zh) 2018-01-02
JP2018513175A (ja) 2018-05-24
EP3285774B1 (fr) 2020-01-08
BR112017021586A2 (pt) 2018-07-03
MX2017013453A (es) 2017-12-07
US20180140609A1 (en) 2018-05-24
FR3035326A1 (fr) 2016-10-28
EP3285774A1 (fr) 2018-02-28
RU2017137262A (ru) 2019-05-21
CA2981933A1 (fr) 2016-10-27
AU2016251601A1 (en) 2017-11-30
KR20170139030A (ko) 2017-12-18

Similar Documents

Publication Publication Date Title
IL263556B (en) Compositions comprising bacterial strains of the species blautia hydrogenotrophica for use in treating or preventing irritable bowel syndrome
EP3370748A4 (en) THERAPEUTIC MICROBIOTA FOR THE TREATMENT AND / OR PREVENTION OF FOOD ALLERGY
EP3393475C0 (en) CIFORADENT ALONE OR IN COMBINATION WITH ATEZOLIZUMAB FOR USE IN THE TREATMENT OF CANCER
MA50417A (fr) Procédés d'utilisation d'inhibiteurs de l'ehmt2 dans le traitement ou la prévention de troubles du sang
HUE055334T2 (hu) Szerves vegyületek és azok alkalmazása központi idegrendszeri betegségek kezelésében vagy megelõzésében
PL3896064T3 (pl) Pochodne 4,6-diamino-chinolino-3-karbonitrylu jako modulatory cot w leczeniu choroby leśniowskiego-crohna i wrzodziejącego zapalenia jelita grubego
EP3495400A4 (en) BLOCK COPOLYMERS AND SURFACE TREATMENTS THEREFOR
MA39960A (fr) Composés imidazo[4,5c]quinoline-2-one et leur utilisation dans le traitement du cancer
MA42366A (fr) Dispositif pour traiter, prévenir ou réduire la myopie, ou le risque de celle-ci
FR3029778B1 (fr) Composition cosmetique comprenant des alpha-olefine sulfonates lineaires, des tensioactifs anioniques et des tensioactifs non ioniques et/ou ampho-teres, et procede de traitement cosmetique
MA44762A (fr) Sémaglutide utilisé dans le traitement de maladies cardiovasculaires
FR2999428B1 (fr) Chitine ou derives de chitine pour utilisation dans la prevention et/ou le traitement de parasitoses
EP3579837C0 (en) AXITINIB, NINTEDANIB OR LENVATINIB FOR THE TREATMENT OF ROSACEA AND ATOPIC DERMATITIS
IL263988A (en) Compositions useful in the prevention and/or treatment of osteoarticular inflammation and pain and cartilage damage
EP3322451A4 (en) ELECTROCHEMICAL REDUCTION OR PREVENTING INFECTIONS
EP3431517A4 (en) Copolymer and surface treatment
EP3632431A4 (en) Agent for preventing or treating brain atrophy
EP3848022C0 (en) THERAPEUTIC AGENT FOR USE IN THE TREATMENT OF INFECTION
EP3302474A4 (en) COMPOSITIONS FOR THE TREATMENT OF ATROPHIC VAGINITIS, PERI- AND POSTMENOPAUSAL DYSPAREUNIA AND / OR OOPHORECTORATED WOMEN AND TREATMENT METHODS THEREWITH
EP3427731A4 (en) ADHERENCIES FOR WOMEN'S SPECIFIC PHYSICAL AND / OR PSYCHIC INGREDIENTS SYMPTOMR
EP3302464A4 (en) USE OF CANNABINOIDS FOR THE TREATMENT OF EYE IGNITIONS AND / OR PAIN
FR3041536B1 (fr) Mousse chimique non rincee contenant du trifarotene, et son utilisation dans le traitement de l'acne.
EP3541185A4 (en) USE OF 2-HYDROXYBENZYLAMINE FOR TREATING AND PREVENTING PULMONAL HYPERTENSION
FR3000895B1 (fr) Utilisation d'antidotes d'inhibiteurs de la coagulation indiques dans la prevention ou le traitement de pathologies thromboemboliques
EP3650018A4 (en) USE OF CANNABIDIOL TO TREAT PULMONIC HYPERTENSION

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 2

PLSC Search report ready

Effective date: 20161028

PLFP Fee payment

Year of fee payment: 3

PLFP Fee payment

Year of fee payment: 4

PLFP Fee payment

Year of fee payment: 5

ST Notification of lapse

Effective date: 20201214